PT  - JOURNAL ARTICLE
AU  - Pryma, Daniel A.
AU  - Mandel, Susan J.
TI  - Radioiodine Therapy for Thyroid Cancer in the Era of Risk Stratification and Alternative Targeted Therapies
AID  - 10.2967/jnumed.113.131508
DP  - 2014 Sep 01
TA  - Journal of Nuclear Medicine
PG  - 1485--1491
VI  - 55
IP  - 9
4099  - http://jnm.snmjournals.org/content/55/9/1485.short
4100  - http://jnm.snmjournals.org/content/55/9/1485.full
SO  - J Nucl Med2014 Sep 01; 55
AB  - Differentiated thyroid cancers are typically iodine-avid and can be effectively treated with radioiodine. In most patients, radioiodine treatment is done for ablation of residual tissue, and in these cases the focus should be on using the minimum effective dose. Adjuvant therapy can be done to reduce the risk of recurrence, but optimal patient selection and dose are unclear. Patients with advanced disease benefit most from treatment with the maximum-tolerated dose. Recent research has focused on better patient selection and reduced radioiodine doses for remnant ablation. There are emerging targeted therapeutic approaches in patients who are appropriately shown to have iodine-refractory disease, with 1 drug approved by the Food and Drug Administration. Numerous trials are ongoing to assess targeted therapeutics alone or in combination with radioiodine.